PMID- 20680233
OWN - NLM
STAT- MEDLINE
DCOM- 20100923
LR  - 20111117
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 30
IP  - 3
DP  - 2010 Aug
TI  - Antiphospholipid syndrome. Current insights into laboratory diagnosis and 
      pathophysiology.
PG  - 139-43
AB  - The antiphospholipid syndrome (APS) is a non-inflammatory autoimmune disease 
      characterized by the presence of antiphospholipid antibodies (aPL) in the plasma 
      of patients with vascular thrombosis, recurrent complications of pregnancy, or 
      both (1, 2). The presence of aPL in plasma of patients can be detected with 
      either a prolongation of phospholipid dependent coagulation tests (lupus 
      anticoagulant, LAC), or with solid phase immune assays against the protein 
      beta2-glycoprotein I (beta2-GPI) or the phospholipid cardiolipin (anti-beta2-GPI 
      antibody ELISA and anti-cardiolipin antibody ELISA, respectively) (3). For a long 
      time there was a lot of confusion on who had the syndrome and who not. To solve 
      this dispute, an international consensus meeting was organized in Sapporo in 1999 
      to formulate classification criteria for patients with the antiphospholipid 
      syndrome (4). These criteria have been updated in 2004 at another international 
      consensus meeting in Sydney (5). The classification criteria were defined for 
      scientific purposes and were aimed to be used as inclusion criteria in patient 
      related studies. They were specifically not defined for diagnostic purposes. 
      However, current practice is that these criteria are used as a diagnostic tool. 
      This is very unfortunate because the specificity of the different aPL assays to 
      detect the clinical manifestations that characterize APS are disputable. One of 
      the aims of defining the criteria was to initiate studies to determine the value 
      of the different anti-phospholipid antibody assays to serve as biomarker for the 
      risk of thrombosis and pregnancy morbidity. The recent progress made on this 
      important topic will be discussed.
FAU - van Os, G M A
AU  - van Os GM
AD  - Department of Clinical Chemistry and Haematology, University Medical Center 
      Utrecht, The Netherlands.
FAU - Urbanus, R T
AU  - Urbanus RT
FAU - Agar, C
AU  - Agar C
FAU - Meijers, J C M
AU  - Meijers JC
FAU - de Groot, P G
AU  - de Groot PG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Antibodies, Antiphospholipid)
SB  - IM
MH  - Antibodies, Antiphospholipid/blood/physiology
MH  - Antiphospholipid Syndrome/blood/*diagnosis/*physiopathology
MH  - Clinical Laboratory Techniques
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/blood
EDAT- 2010/08/04 06:00
MHDA- 2010/09/24 06:00
CRDT- 2010/08/04 06:00
PHST- 2010/08/04 06:00 [entrez]
PHST- 2010/08/04 06:00 [pubmed]
PHST- 2010/09/24 06:00 [medline]
AID - 10030139 [pii]
PST - ppublish
SO  - Hamostaseologie. 2010 Aug;30(3):139-43.